|
Price: $1.5000
$-0.09 
-5.660%
|
| Day's High:
| $1.57
| Week Perf:
| -10.71 %
|
| Day's Low: |
$ 1.50 |
30 Day Perf: |
-14.29 % |
| Volume (M): |
0 |
52 Wk High: |
$ 19.23 |
| Volume (M$): |
$ 1 |
52 Wk Avg: |
$8.68 |
| Open: |
$1.57 |
52 Wk Low: |
$1.38 |
|
|
| Market Capitalization (Millions $) |
1 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
51 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-34 |
| Cash Flow (TTM) (Millions $) |
-21 |
| Capital Exp. (TTM) (Millions $) |
0 |
Trevena Inc
Trevena Inc. is a pharmaceutical company located in Pennsylvania, USA that is focused on discovering, developing and commercializing therapies for serious medical conditions. The company was founded in 2008 and is publicly traded on the NASDAQ stock exchange under the symbol TRVN.
Trevena is dedicated to advancing the care of patients suffering from pain, heart failure, and other conditions that have a significant impact on overall health and quality of life. The company's innovative drug discovery platform is based on a deep understanding of chemical biology and molecular pharmacology, which enables the development of highly specific and effective therapies.
The company's lead product candidate is OLINVYKe (oliceridine), which is a new pain reliever that has been approved by the U.S. Food and Drug Administration (FDA). OLINVYK is specifically designed to address the limitations of traditional opioid analgesics by providing rapid and effective pain relief, while also minimizing common side effects such as respiratory depression, nausea, and vomiting.
In addition to OLINVYK, Trevena has a strong pipeline of product candidates that are currently in various stages of development. These include TRV027, which is being developed for the treatment of acute heart failure, and TRV250, which is being developed for the treatment of migraine headaches.
Trevena's mission is to improve the lives of patients by developing and commercializing innovative therapies that address unmet medical needs. The company is committed to maintaining the highest standards of scientific excellence and ethical conduct, and is dedicated to working collaboratively with healthcare providers, patients, and other stakeholders to achieve its goals.
Company Address: 955 Chesterbrook Boulevard, Suite 110 Chesterbrook 19087 PA
Company Phone Number: 354-8840 Stock Exchange / Ticker: TRVN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stock Market Announcement
Published Fri, Oct 4 2024 8:05 PM UTC
Chesterbrook, Pa. Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, has recently received a discouraging notice from the Nasdaq Hearings Panel regarding the status of its stock listing. On October 4, 2024, the Panel informed Trevena that it would be delisting the company?s com...
|
| Shares
Published Thu, Aug 8 2024 8:05 PM UTC
Trevena Announces Reverse Stock Split: A Strategic Move Towards Compliance and Growth
CHESTERBROOK, Pa., Aug. 08, 2024 - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company specializing in the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders, has recently announced its decision to implement a reverse...
|
| Financing Agreement
Published Mon, Jul 8 2024 1:15 PM UTC
Trevena Inc., a renowned biopharmaceutical company focused on developing innovative therapies, has recently announced a significant financial milestone as part of its ongoing efforts to advance its lead product, OLINVYK, and achieve commercialization success in the United States. The company expects to receive a non-dilutive $2 million tranche, with the potential f...
|
| Trevena Inc
Trevena Inc., a biopharmaceutical company focused on developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, recently announced the successful closure of its private placement offering. The offering involved the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants) along with warrants to purchase up to an aggregate of 2,779,906 shares of common stock. The purchase price was set at $0.70 per share or warrant, resulting in gross proceeds of approximately $1.946 million for the company.
This private placement marks a significant milestone for Trevena Inc. as it enhances the company's financial position and provides additional resources to support its continued growth and development efforts. The funds raised through this offering will be allocated towards advancing the company's pipeline of CNS disorder treatments, furthering its mission of bringing novel medicines to patients in need. This injection of capital will undoubtedly have a positive impact on the company's future results and its ability to continue its important work in the field.
|
| Trevena Inc
TRV045, a novel S1P receptor modulator developed by Trevena Inc., is gaining traction in both non-clinical and clinical studies, showing promising potential for treating chronic pain and epilepsy. As the biopharmaceutical company advances toward important milestones, Trevena recently closed a private placement offering, raising $1.946 million and improving its leverage ratio performance.
Trevena Inc., headquartered in Chesterbrook, Pennsylvania, is dedicated to the development and commercialization of innovative medicines for patients suffering from central nervous system (CNS) disorders. The successful closing of the private placement offering involved the issuance and sale of 2,779,906 shares of common stock or pre-funded warrants, along with warrants for the purchase of up to 2,779,906 shares of common stock. Priced at $0.70 per share or warrant, the offering generated gross proceeds of approximately $1.946 million for the company.
|
| Per Share |
Current |
| Earnings (TTM) |
-46.69 $ |
| Revenues (TTM) |
0.12 $
|
| Cash Flow (TTM) |
- |
| Cash |
15.79 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-46.69 $
|
| Revenues (TTM) |
0.12 $ |
| Cash Flow (TTM) |
- |
| Cash |
15.79 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
